Reference 2021-67

REF: 2021-67          

Subject: Researching on the incidence and treatment of breast cancer                 

 

Request:

I am researching the incidence and treatment of breast cancer.  Could you please provide the number of patients that you have treated in the past three months with the following:

·         Abemaciclib + Anastrozole/Exemestane/Letrozole

·         Abemaciclib + Fulvestrant

·         Alpelisib + Fulvestrant

·         Atezolizumab

·         Bevacizumab

·         Eribulin

·         Everolimus + Exemestane

·         Fulvestrant as a single agent

·         Gemcitabine + Paclitaxel

·         Lapatinib

·         Neratinib

·         Olaparib

·         Palbociclib + Anastrozole/Exemestane/Letrozole

·         Palbociclib  + Fulvestrant

·         Pertuzumab + Trastuzumab + Docetaxel

·         Ribociclib + Anastrozole/Exemestane/Letrozole

·         Ribociclib + Fulvestrant

·         Talazoparib

·         Transtuzumab + Paclitaxel

·         Transtuzumab as a single agent

·         Trastuzumab emtansine

·         Any other active

 

Response:

Could you please provide the number of patients that you have treated in the past three months with the following:

·         Abemaciclib + Anastrozole/Exemestane/Letrozole

0

·         Abemaciclib + Fulvestrant

0

·         Alpelisib + Fulvestrant

0

·         Atezolizumab

0

·         Bevacizumab

0

·         Eribulin

0

·         Everolimus + Exemestane

0

·         Fulvestrant as a single agent

0

·         Gemcitabine + Paclitaxel

0

·         Lapatinib

0

·         Neratinib

0

·         Olaparib

0

·         Palbociclib + Anastrozole/Exemestane/Letrozole

0

·         Palbociclib  + Fulvestrant

0

·         Pertuzumab + Trastuzumab + Docetaxel

0

·         Ribociclib + Anastrozole/Exemestane/Letrozole

0

·         Ribociclib + Fulvestrant

0

·         Talazoparib

0

·         Transtuzumab + Paclitaxel

0

·         Transtuzumab as a single agent

0

·         Trastuzumab emtansine

0

·         Any other active systemic anti-cancer therapy

69